A Multicentre, Double Blind, Comparative, Randomised Study to evaluate the Efficacy and Safety of Micafungin (FK463) Versus Liposomal Amphotericin B (Ambisome) in the Treatment of Invasive Candidiasis and Candidaemia

Grants and Contracts Details

StatusFinished
Effective start/end date10/20/03 → 6/30/06

Funding

  • Fujisawa Pharmaceuticals: $17,140.00